Cutaneous melanoma, also called malignant melanoma, is the type of skin cancer that is most likely to spread to other parts of the body. Though melanoma accounts for only about 1% of skin cancers, it is responsible for more than 90% of skin cancer-related deaths.
But thanks to developments in skin cancer treatment (mostly in the last decade), patients with melanoma have much better chances of living longer.
What is a melanoma?
Melanoma involves the uncontrolled growth of a type of cell known as a melanocyte. One of the most important functions of a normal melanocyte is to protect your skin from the sun’s damaging ultraviolet (UV) rays. It does this by producing melanin pigment. (Though we usually refer to melanoma of the skin, melanomas can also develop from melanocytes in other parts of the body, such as the retina or gastrointestinal tract.)
There are many factors that may result in the development of melanomas. These include environmental factors such as sun damage or use of tanning beds; immune suppression; genetic causes, such as inheritance of a gene that makes you more susceptible to melanomas; and spontaneous gene mutations.
Treatment options: The old and the new
Until several years ago, treatment options for people with advanced metastatic disease (melanoma that has spread to other parts of the body) were quite limited. Surgical removal of the cancer, chemotherapy, and less targeted immunotherapy and interferon therapy (to reduce tumor proliferation) were possible treatment options. But only about one in 10 patients with advanced metastatic disease survived for five years, and median survival was less than one year.
Thanks to significant developments in genetic research, including findings from the Human Genome Project, patients with widespread disease now have a much better chance of survival. For example, research showing that some melanomas have mutations that abnormally activate certain signaling pathways, which contribute to uncontrolled tumor growth, has led to advances in targeted immunotherapy.
Newer therapies targeting these pathways, and immune checkpoint inhibitors that block specific targets in tumor production pathways, are now available to treat advanced melanoma. These include kinase inhibitors such as dabrafenib (Tafinlar) and vemurafenib (Zelboraf), and immune checkpoint inhibitors such as nivolumab (Opdivo), pembrolizumab (Keytruda), and ipilimumab (Yervoy).
A study examining one of these newer therapies showe
